5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland
Inoue, K.; Horikoshi, N.; Mukaiyama, T.; Ogawa, M.; Kuraishi, Y.
Gan no Rinsho. Japan Journal of Cancer Clinics 35(4): 481-485
1989
ISSN/ISBN: 0021-4949 PMID: 2654442 Document Number: 343817
An adenocarcinoma of the parotid gland is a rare tumor and little is known about the efficacy of chemotherapy as a method of treatment. Four patients with a metastatic, or recurrent adenocarcinoma of the parotid gland were treated with a combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin C (FAM): 5-fluorouracil 330-500 mg/m2, d1-3, q3w or tegafur 400-600 mg/m2 p.o. adriamycin 30-40 mg/m2 q3w, and mitomycin C 3-10 mg/m2, q1-2w. One patient with a lung metastasis showed a good partial response lasting for 19 months and another patient who was resistant to CDDP plus the adriamycin combination, having a lymph node, bone, and bone marrow metastases, had a partial response lasting for 31 months. Results have indicated that adriamycin is one of the effective therapeutic drugs and that FAM combination chemotherapy can provide some efficacy against a parotid cancer.